Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine augmentation in Alzheimer's Disease
NCT00191009Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Atomoxetine with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive at 6 months. Started Oct 2003; status: completed.
02
Drugs
atomoxetine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00191009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191009.